Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nasdaq Biotechnology Ishares ETF (IBB)

Nasdaq Biotechnology Ishares ETF (IBB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family BlackRock iShares
  • Assets Under Management 6,358,432,800
  • Shares Outstanding, K 47,250
  • 60-Month Beta 0.84
  • Price/Earnings ttm 15.68
  • Annual Dividend & Yield 0.38 (0.28%)
  • Most Recent Dividend 0.121 on 03/18/25
  • Management Fee 0.44%
  • INDUSTRY GROUPING:

    ETFs - Biotech

Options Overview Details

View History
  • Implied Volatility 20.76% ( -1.40%)
  • Historical Volatility 18.06%
  • IV Percentile 72%
  • IV Rank 32.13%
  • IV High 33.78% on 08/05/24
  • IV Low 14.59% on 07/10/24
  • Put/Call Vol Ratio 0.94
  • Today's Volume 629
  • Volume Avg (30-Day) 6,099
  • Put/Call OI Ratio 1.65
  • Today's Open Interest 141,868
  • Open Int (30-Day) 134,501

Price Performance

See More
Period Period Low Period High Performance
1-Month
132.12 +1.85%
on 03/11/25
140.73 -4.38%
on 02/21/25
-4.17 (-3.01%)
since 02/19/25
3-Month
130.51 +3.11%
on 12/20/24
142.80 -5.76%
on 02/06/25
+3.36 (+2.56%)
since 12/19/24
52-Week
123.60 +8.88%
on 04/19/24
150.57 -10.62%
on 09/19/24
-1.57 (-1.15%)
since 03/19/24

Most Recent Stories

More News
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic

For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.

IBB : 134.57 (+0.36%)
FNDF : 37.45 (+0.29%)
PFE : 26.21 (-0.38%)
BNTX : 99.27 (+0.31%)
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential

The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.

IBB : 134.57 (+0.36%)
EDIT : 1.3900 (+5.70%)
VTI : 279.41 (+1.14%)
IWM : 206.37 (+1.56%)
4 Sectors That Thrive When Inflation Runs Hot

Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value

MDLZ : 64.00 (-1.01%)
KMB : 139.65 (+0.09%)
MRK : 94.02 (-0.74%)
PG : 168.57 (+0.51%)
NEM : 47.99 (+0.38%)
IBB : 134.57 (+0.36%)
PEP : 148.11 (-0.59%)
FCX : 40.42 (+1.46%)
ABBV : 212.25 (-0.75%)
NEE : 70.50 (-0.28%)
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz?

The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder.

VXF : 178.62 (+1.72%)
IBB : 134.57 (+0.36%)
PEPG : 2.02 (-7.34%)
IWM : 206.37 (+1.56%)
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?

Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.

SLDB : 4.82 (-2.23%)
VXF : 178.62 (+1.72%)
IBB : 134.57 (+0.36%)
VTI : 279.41 (+1.14%)
IWM : 206.37 (+1.56%)
Bio-Techne Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Bio-Techne's underperformance relative to the broader market over the past year, Wall Street analysts remain bullish on the stock's prospects.

TECH : 60.89 (-3.09%)
$SPX : 5,675.29 (+1.08%)
IBB : 134.57 (+0.36%)
IBB : 134.57 (+0.36%)
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

TCAF : 32.74 (+0.89%)
ASND : 166.05 (+0.85%)
IBB : 134.57 (+0.36%)
HRTS : 30.05 (+0.20%)
Tempus AI Stock Swings Wildly As Earnings Near, Retail’s Cautiously Optimistic After Insider Sales

The company has gained a lot of attention since launching an AI-enabled personal health app last month.

ARKG : 23.10 (+1.99%)
IBB : 134.57 (+0.36%)
VTI : 279.41 (+1.14%)
TEM : 48.03 (+5.01%)
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

ARKG : 23.10 (+1.99%)
IBB : 134.57 (+0.36%)
XBI : 87.46 (+1.50%)
NTLA : 9.30 (+1.20%)
There May Still Be Time to Get in on These 3 Trending Biotechs

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

AVDL : 8.77 (+1.62%)
SANA : 2.34 (+2.63%)
IBB : 134.57 (+0.36%)
ADMA : 20.61 (+10.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The iShares Nasdaq Biotechnology ETF seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology...

See More

Key Turning Points

3rd Resistance Point 137.05
2nd Resistance Point 136.00
1st Resistance Point 135.29
Last Price 134.57
1st Support Level 133.53
2nd Support Level 132.48
3rd Support Level 131.77

See More

52-Week High 150.57
Fibonacci 61.8% 140.26
Fibonacci 50% 137.08
Last Price 134.57
Fibonacci 38.2% 133.90
52-Week Low 123.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar